Table 1.
Patient Characteristics (n = 9143)
| Factors | Total (n = 9143) | Candidemia (n = 358) | No candidemia (n = 8785) | P Value | ||||
|---|---|---|---|---|---|---|---|---|
| Age, y | Median | 51 | 0–85 | 53 | 7–80 | 50 | 0–85 | <.001 |
| <50 | 4370 | (47.8) | 142 | (39.7) | 4228 | (48.1) | .002 | |
| ≥50 | 4773 | (69.5) | 216 | (60.3) | 4557 | (51.9) | ||
| Sex | Male | 5568 | (60.9) | 224 | (62.6) | 5344 | (60.8) | .54 |
| Female | 3575 | (39.1) | 134 | (37.4) | 3441 | (39.2) | ||
| Disease | AML | 4238 | (46.4) | 195 | (54.5) | 4043 | (46.0) | .002 |
| ALL | 1822 | (19.9) | 60 | (16.8) | 1762 | (20.1) | ||
| MDS | 1297 | (14.2) | 32 | (8.9) | 1265 | (14.4) | ||
| ML | 1786 | (19.5) | 71 | (19.8) | 1715 | (19.5) | ||
| Disease risk | Standard | 3983 | (46.4) | 111 | (32.5) | 3872 | (47.0) | <.001 |
| High | 4604 | (53.6) | 231 | (67.5) | 4373 | (53.0) | ||
| NA | 556 | 16 | 540 | |||||
| No. of HCTs | First | 7531 | (82.4) | 274 | (76.5) | 7257 | (82.6) | .005 |
| Second | 1612 | (17.6) | 84 | (23.5) | 1528 | (17.4) | ||
| Donor | MRD | 5280 | (20.1) | 32 | (8.9) | 1322 | (15.0) | <.001 |
| MMRD | 2653 | (10.1) | 42 | (11.7) | 1401 | (15.9) | ||
| MUD | 5943 | (22.7) | 44 | (12.3) | 1586 | (18.1) | ||
| MMUD | 3555 | (13.6) | 32 | (8.9) | 1062 | (12.1) | ||
| CB | 8805 | (33.6) | 208 | (58.1) | 3414 | (38.9) | ||
| Conditioning | MAC | 5365 | (58.7) | 201 | (56.1) | 5164 | (58.8) | .33 |
| RIC | 3778 | (41.3) | 157 | (43.9) | 3621 | (41.2) | ||
| T-cell depletion | No | 7857 | (85.9) | 319 | (89.1) | 7538 | (85.8) | .088 |
| Yes | 1286 | (14.1) | 39 | (10.9) | 1247 | (14.2) | ||
| TBI >8 Gy | No | 6818 | (74.6) | 285 | (79.6) | 6533 | (74.4) | .026 |
| Yes | 2325 | (25.4) | 73 | (20.4) | 2252 | (25.6) | ||
| HCT-CI minus pulmonary component | 0 | 5358 | (59.5) | 137 | (39.4) | 5221 | (60.3) | <.001 |
| ≥1 | 3649 | (40.5) | 211 | (60.6) | 3438 | (39.7) | ||
| NA | 136 | 10 | 126 | |||||
| Pulmonary comorbidity | No | 7141 | (79.0) | 251 | (71.9) | 6890 | (79.3) | .001 |
| Yes | 1897 | (21.0) | 98 | (28.1) | 1799 | (20.7) | ||
| NA | 105 | 9 | 96 | |||||
| PS | 0–1 | 7562 | (82.8) | 252 | (70.4) | 7310 | (83.3) | <.001 |
| ≥2 | 1572 | (17.2) | 106 | (29.6) | 1466 | (16.7) | ||
| NA | 9 | 0 | 9 | |||||
| CMV serostatus, P/D | +/+ | 2744 | (33.0) | 57 | (17.6) | 2687 | (33.7) | <.001 |
| +/− | 4152 | (50.0) | 217 | (67.0) | 3935 | (49.3) | ||
| −/+ | 430 | (5.2) | 14 | (4.3) | 416 | (5.2) | ||
| −/− | 977 | (11.8) | 36 | (11.1) | 941 | (11.8) | ||
| NA | 840 | 34 | 806 | |||||
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CB, cord blood; CMV, cytomegalovirus; D, donor; HCT, hematopoietic cell transplantation; HCT-CI, hematopoietic cell transplantation-specific comorbidity index; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; ML, malignant lymphoma; MMRD, HLA-mismatched related donor; MMUD, HLA-mismatched unrelated donor; MRD, HLA-matched related donor; MUD, HLA-matched unrelated donor; NA, not available; P, patient; PS, performance status; RIC, reduced-intensity conditioning; TBI, total body irradiation.